Protagonist Therapeutics, Inc. reported a significant decline in its financial performance for the fiscal year ending December 31, 2025, with total revenue dropping to $46.0 million from $434.4 million in the previous year. This decrease was primarily attributed to a lack of milestone payments from its collaboration with Johnson & Johnson (JNJ), which had contributed $165.0 million in 2024. The company’s operating expenses also increased, rising by 12% to $204.1 million, driven by higher research and development costs associated with ongoing clinical trials and new product candidates. The net loss for the year was $130.1 million, compared to a net income of $275.2 million in 2024.
In terms of strategic developments, Protagonist has made notable progress in its product pipeline. The company is advancing its investigational drug candidates, including Icotyde™ (icotrokinra) and rusfertide, both of which are in late-stage clinical trials. JNJ submitted a New Drug Application (NDA) for Icotyde in July 2025, while Takeda Pharmaceuticals submitted an NDA for rusfertide in December 2025. The company expects to launch both products in the U.S. in 2026, pending regulatory approval. Additionally, Protagonist is developing several other candidates, including PN-881, PN-477, and PN-458, which target various therapeutic areas such as inflammation, obesity, and metabolic diseases.
Operationally, Protagonist's workforce has grown to 132 full-time employees, with 103 dedicated to research and development. The company ended the fiscal year with cash, cash equivalents, and marketable securities totaling approximately $646.0 million, an increase from $559.2 million in 2024. This financial cushion is expected to support ongoing clinical trials and development activities. The company also anticipates receiving significant milestone and royalty payments from its collaborations with JNJ and Takeda, contingent upon successful product launches.
Looking ahead, Protagonist's management expressed optimism about the potential for future revenue generation from its product candidates, particularly if they receive regulatory approval. However, the company remains aware of the inherent risks associated with clinical development, including the possibility of delays or failures in obtaining necessary approvals. The management's discussion highlighted the need for continued investment in research and development to advance its pipeline and address unmet medical needs in the therapeutic areas it targets.
In summary, while Protagonist Therapeutics faced a challenging fiscal year with a substantial net loss and decreased revenue, it continues to advance its promising product candidates and maintain a strong financial position, setting the stage for potential future growth contingent on regulatory approvals and successful commercialization efforts.
About Protagonist Therapeutics, Inc
Protagonist Therapeutics is a biopharmaceutical company focused on discovering and developing peptide-based therapeutics for hematology, inflammatory, and immunomodulatory diseases. Its pipeline includes novel peptides like rusfertide for polycythemia vera and icotrokinra for psoriasis and other inflammatory conditions. The company leverages proprietary peptide technology to create oral and injectable drugs, collaborating with partners like Takeda and J&J to address unmet medical needs in chronic diseases.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.